A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy

Purpose: To establish the safety, tolerability, pharmacokinetics, and pharmacodynamics of an intravitreal injection of recombinant human complement factor H (CFH), GEM103, in individuals with genetically defined age-related macular degeneration (AMD) and geographic atrophy (GA). Design: Phase I sing...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Arshad M. Khanani, MD, MA, Raj K. Maturi, MD, Nika Bagheri, MD, Benjamin Bakall, MD, PhD, David S. Boyer, MD, Stephen S. Couvillion, MD, Dilsher S. Dhoot, MD, Nancy M. Holekamp, MD, Karim N. Jamal, MD, Dennis M. Marcus, MD, Dante Pieramici, MD, Aamir A. Aziz, BS, Kiran C. Patki, MD, William Z. Bridges, Jr., MD, Samuel B. Barone, MD
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2022-06-01
Serier:	Ophthalmology Science
Fag:	Age-related macular degeneration Complement factor H Complement regulation GEM103 Geographic atrophy
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2666914522000434
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!